SCHEMBL4390898

SCHEMBL4390898

Clc1ccc2cc(CBr)ccc2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 2/20 0.50
KMT2A Q03164 1/20 0.36
TEC P42680 1/20 0.36
IDO1 P14902 1/20 0.36
CYP1A2 P05177 2/20 0.36
OPRL1 P41146 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
CYP2C19 P33261 1/20 0.36
SLC6A3 Q01959 1/20 0.36
F11 P03951 1/20 0.35
CYP4F2 P78329 1/20 0.35
CYP4A11 Q02928 1/20 0.35
NR1D1 P20393 1/20 0.35
AHR P35869 2/20 0.34
CMA1 P23946 1/20 0.34
F7 P08709 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29707612 0.85 CYP1A2 (0.44) CYP2A6KMT2ACYP1A2CYP3A4SLC6A2
SCHEMBL1721014 0.85 CYP1A2 (0.44) CYP2A6KMT2ACYP1A2CYP3A4SLC6A2
SCHEMBL24214997 0.82 CYP4F2 (0.39) CYP2A6KMT2AIDO1CYP1A2CYP3A4
SCHEMBL5349984 0.80 CYP1A2 (0.41) CYP2A6CYP1A2CYP3A4SLC6A2SLC6A3
SCHEMBL6211230 0.79 CYP2A6 (0.52) CYP2A6KMT2ATECIDO1CYP1A2
SCHEMBL31069470 0.78 CYP1A2 (0.42) CYP2A6CYP1A2TRPA1ALDH1A1TSHR
SCHEMBL2888187 0.78 CYP1A2 (0.42) CYP2A6CYP1A2TRPA1ALDH1A1TSHR
SCHEMBL15351609 0.77 CYP2A6 (0.50) CYP2A6KMT2ATECIDO1CYP1A2
SCHEMBL21584423 0.77 IDO1 (0.58) CYP2A6KMT2ATECIDO1CYP1A2
SCHEMBL15352347 0.77 CYP2A6 (0.50) CYP2A6KMT2ATECIDO1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612075-B2 Substituted oxoazaheterocyclyl compounds AVENTIS PHARMACEUTICALS INC. (US) 2009-11-03 US disclosed
US-20040102450-A1 Substituted oxoazaheterocyclyl compounds AVENTIS PHARMACEUTICALS INC. (US) 2004-05-27 US disclosed
EP-1051176-A4 SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS AVENTIS PHARM PROD INC (US) 2002-06-12 EP disclosed
EP-1208097-A2 SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS Aventis Pharmaceuticals Inc. (US) 2002-05-29 EP disclosed
WO-2001007436-A2 SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS AVENTIS PHARMACEUTICALS INC. (US) 2001-02-01 WO disclosed
EP-1051176-A1 SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS Aventis Pharmaceuticals Products Inc. (US) 2000-11-15 EP disclosed
WO-2000032590-A1 SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) 2000-06-08 WO disclosed
WO-1999037304-A1 SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) 1999-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040102450-A1 Substituted oxoazaheterocyclyl compounds F13B, F9, F11 CYP2A6 165/4885KMT2A 2513/4885TEC 3496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.